Skip to main content
Top
Published in: Virology Journal 1/2016

Open Access 01-12-2016 | Research

Statistical correlation of nonconservative substitutions of HIV gp41 variable amino acid residues with the R5X4 HIV-1 phenotype

Authors: Elena Pacheco-Martínez, Evangelina Figueroa-Medina, Carlos Villarreal, Germinal Cocho, José L. Medina-Franco, Oscar Méndez-Lucio, Leonor Huerta

Published in: Virology Journal | Issue 1/2016

Login to get access

Abstract

Background

The interaction of the envelope glycoprotein of HIV-1 (gp120/gp41) with coreceptor molecules has important implications for specific cellular targeting and pathogenesis. Experimental and theoretical evidences have shown a role for gp41 in coreceptor tropism, although there is no consensus about the positions involved. Here we analyze the association of physicochemical properties of gp41 amino acid residues with viral tropism (X4, R5, and R5X4) using a large set of HIV-1 sequences. Under the assumption that conserved regions define the complex structural features essential for protein function, we focused our search only on amino acids in the gp41 variable regions.

Methods

Gp41 amino acid sequences of 2823 HIV-1 strains from all clades with known coreceptor tropism were retrieved from Los Alamos HIV Database. Consensus sequences were constructed for homologous sequences (those obtained from the same patient and having the same tropism) in order to avoid bias due to sequence overrepresentation, and the variability (entropy) per site was determined. Comparisons of hydropathy index (HI) and charge (Q) of amino acid residues at highly variable positions between coreceptor groups were performed using two non-parametrical tests and Benjamini-Hochberg correction. Pearson’s correlation analysis was performed to determine covariance of HI and Q values.

Results

Calculation of variability per site rendered 58 highly variable amino acid positions. Of these, statistical analysis rendered significantly different HI or Q only for the R5 vs. R5X4 comparison at twelve positions: 535, 602, 619, 636, 640, 641, 658, 662, 667, 723, 756 and 841. The largest differences in particular amino acid frequencies between coreceptor groups were found at 619, 636, 640, 641, 662, 723 and 756. A hydrophobic tendency of residues 619, 640, 641, 723 and 756, along with a hydrophilic/charged tendency at residues 636 and 662 was observed in R5X4 with respect to R5 sequences. HI of position 640 covariated with that of 602, 619, 636, 662, and 756.

Conclusions

Variability and significant correlations of physicochemical properties with viral phenotype suggest that substitutions at residues in the loop (602 and 619), the HR2 (636, 640, 641, 662), and the C-terminal tail (723, 756) of gp41 may contribute to phenotype of R5X4 strains.
Appendix
Available only for authorised users
Literature
2.
go back to reference Steckbeck JD, Craigo JK, Barnes CO, Montelaro RC. Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication. J Biol Chem. 2011;286(31):27156–66.PubMedCentralCrossRefPubMed Steckbeck JD, Craigo JK, Barnes CO, Montelaro RC. Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication. J Biol Chem. 2011;286(31):27156–66.PubMedCentralCrossRefPubMed
3.
go back to reference Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 1998;280(5371):1949–53.CrossRefPubMed Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 1998;280(5371):1949–53.CrossRefPubMed
5.
go back to reference Chien MP, Jiang S, Chang DK. The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. FASEB J. 2008;22(4):1179–92.CrossRefPubMed Chien MP, Jiang S, Chang DK. The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. FASEB J. 2008;22(4):1179–92.CrossRefPubMed
6.
go back to reference Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV’s switch-hitter. AIDS Res Hum Retroviruses. 2005;21(2):171–89.CrossRefPubMed Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV’s switch-hitter. AIDS Res Hum Retroviruses. 2005;21(2):171–89.CrossRefPubMed
7.
go back to reference Edo-Matas D, Rachinger A, Setiawan LC, Boeser-Nunnink BD, van’t Wout AB, Lemey P, et al. The evolution of human immunodeficiency virus type-1 (HIV-1) envelope molecular properties and coreceptor use at all stages of infection in an HIV-1 donor-recipient pair. Virology. 2012;422(1):70–80.CrossRefPubMed Edo-Matas D, Rachinger A, Setiawan LC, Boeser-Nunnink BD, van’t Wout AB, Lemey P, et al. The evolution of human immunodeficiency virus type-1 (HIV-1) envelope molecular properties and coreceptor use at all stages of infection in an HIV-1 donor-recipient pair. Virology. 2012;422(1):70–80.CrossRefPubMed
8.
go back to reference Ghaffari G, Tuttle DL, Briggs D, Burkhardt BR, Bhatt D, Andiman WA, et al. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. J Virol. 2005;79(21):13250–61.PubMedCentralCrossRefPubMed Ghaffari G, Tuttle DL, Briggs D, Burkhardt BR, Bhatt D, Andiman WA, et al. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. J Virol. 2005;79(21):13250–61.PubMedCentralCrossRefPubMed
9.
go back to reference Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol. 2004;78(1):524–30.PubMedCentralCrossRefPubMed Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol. 2004;78(1):524–30.PubMedCentralCrossRefPubMed
10.
go back to reference Edo-Matas D, van Dort KA, Setiawan LC, Schuitemaker H, Kootstra NA. Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. Virology. 2011;412(2):269–77.CrossRefPubMed Edo-Matas D, van Dort KA, Setiawan LC, Schuitemaker H, Kootstra NA. Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. Virology. 2011;412(2):269–77.CrossRefPubMed
11.
go back to reference Daumer M, Kaiser R, Klein R, Lengauer T, Thiele B, Thielen A. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak. 2011;11:30.PubMedCentralCrossRefPubMed Daumer M, Kaiser R, Klein R, Lengauer T, Thiele B, Thielen A. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak. 2011;11:30.PubMedCentralCrossRefPubMed
12.
go back to reference Seclen E, Soriano V, Gonzalez MM, Gomez S, Thielen A, Poveda E. High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J Clin Microbiol. 2011;49(9):3380–2.PubMedCentralCrossRefPubMed Seclen E, Soriano V, Gonzalez MM, Gomez S, Thielen A, Poveda E. High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J Clin Microbiol. 2011;49(9):3380–2.PubMedCentralCrossRefPubMed
13.
go back to reference Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol. 2008;82(11):5584–93.PubMedCentralCrossRefPubMed Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol. 2008;82(11):5584–93.PubMedCentralCrossRefPubMed
14.
go back to reference Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, et al. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res. 2011;90(1):42–53.CrossRefPubMed Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, et al. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res. 2011;90(1):42–53.CrossRefPubMed
15.
go back to reference Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJ, Moore JP. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology. 2011;413(1):47–59.PubMedCentralCrossRefPubMed Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJ, Moore JP. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology. 2011;413(1):47–59.PubMedCentralCrossRefPubMed
16.
go back to reference Taylor BM, Foulke JS, Flinko R, Heredia A, DeVico A, Reitz M. An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J Virol. 2008;82(11):5460–71.PubMedCentralCrossRefPubMed Taylor BM, Foulke JS, Flinko R, Heredia A, DeVico A, Reitz M. An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J Virol. 2008;82(11):5460–71.PubMedCentralCrossRefPubMed
17.
go back to reference Sanders RW, Korber B, Lu M, Berkhout B, Moore JP. Mutational Analyses and Natural Variability of the gp41 Ectodomain. In: Publishing D, editor. HIV Molecular Immunology 2002. Los Alamos National Laboratory, New Mexico: DIANE Publishing; 2002. Sanders RW, Korber B, Lu M, Berkhout B, Moore JP. Mutational Analyses and Natural Variability of the gp41 Ectodomain. In: Publishing D, editor. HIV Molecular Immunology 2002. Los Alamos National Laboratory, New Mexico: DIANE Publishing; 2002.
18.
go back to reference Diez-Fuertes F, Delgado E, Vega Y, Fernandez-Garcia A, Cuevas MT, Pinilla M, et al. Improvement of HIV-1 coreceptor tropism prediction by employing selected nucleotide positions of the env gene in a Bayesian network classifier. J Antimicrob Chemother. 2013;68(7):1471–85.CrossRefPubMed Diez-Fuertes F, Delgado E, Vega Y, Fernandez-Garcia A, Cuevas MT, Pinilla M, et al. Improvement of HIV-1 coreceptor tropism prediction by employing selected nucleotide positions of the env gene in a Bayesian network classifier. J Antimicrob Chemother. 2013;68(7):1471–85.CrossRefPubMed
19.
go back to reference Dimonte S, Mercurio F, Svicher V, D’Arrigo R, Perno C-F, Ceccherini-Silberstein F. Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120(V3)signatures in the regulation of Co-Receptor usage. Retrovirology. 2011;8:33.PubMedCentralCrossRefPubMed Dimonte S, Mercurio F, Svicher V, D’Arrigo R, Perno C-F, Ceccherini-Silberstein F. Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120(V3)signatures in the regulation of Co-Receptor usage. Retrovirology. 2011;8:33.PubMedCentralCrossRefPubMed
20.
go back to reference Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, et al. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially. Antivir Ther. 2011;16(3):319–28.CrossRefPubMed Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, et al. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially. Antivir Ther. 2011;16(3):319–28.CrossRefPubMed
21.
go back to reference Aiamkitsumrit B, Dampier W, Antell G, Rivera N, Martin-Garcia J, Pirrone V, et al. Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res. 2014;12(2):132–61.PubMedCentralCrossRefPubMed Aiamkitsumrit B, Dampier W, Antell G, Rivera N, Martin-Garcia J, Pirrone V, et al. Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res. 2014;12(2):132–61.PubMedCentralCrossRefPubMed
22.
go back to reference Jiang X, Feyertag F, Meehan C, McCormack G, Travers SA, Craig C et al. Characterising the diverse mutational pathways associated with R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor. J Virol. 2015;89(22):11457-72. Jiang X, Feyertag F, Meehan C, McCormack G, Travers SA, Craig C et al. Characterising the diverse mutational pathways associated with R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor. J Virol. 2015;89(22):11457-72.
23.
go back to reference Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD, et al. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986;5(11):3065–71.PubMedCentralPubMed Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD, et al. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986;5(11):3065–71.PubMedCentralPubMed
24.
go back to reference Cleveland SM, McLain L, Cheung L, Jones TD, Hollier M, Dimmock NJ. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol. 2003;84(3):591–602.CrossRefPubMed Cleveland SM, McLain L, Cheung L, Jones TD, Hollier M, Dimmock NJ. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol. 2003;84(3):591–602.CrossRefPubMed
25.
go back to reference Heap CJ, Reading SA, Dimmock NJ. An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion. J Gen Virol. 2005;86(Pt 5):1499–507.CrossRefPubMed Heap CJ, Reading SA, Dimmock NJ. An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion. J Gen Virol. 2005;86(Pt 5):1499–507.CrossRefPubMed
26.
go back to reference Hollier MJ, Dimmock NJ. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function. Virology. 2005;337(2):284–96.CrossRefPubMed Hollier MJ, Dimmock NJ. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function. Virology. 2005;337(2):284–96.CrossRefPubMed
27.
go back to reference York J, Nunberg JH. Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41. J Virol. 2004;78(9):4921–6.PubMedCentralCrossRefPubMed York J, Nunberg JH. Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41. J Virol. 2004;78(9):4921–6.PubMedCentralCrossRefPubMed
28.
go back to reference Pascual R, Moreno MR, Villalain J. A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism. J Virol. 2005;79(8):5142–52.PubMedCentralCrossRefPubMed Pascual R, Moreno MR, Villalain J. A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism. J Virol. 2005;79(8):5142–52.PubMedCentralCrossRefPubMed
29.
go back to reference Qiu J, Ashkenazi A, Liu S, Shai Y. Structural and functional properties of the membranotropic HIV-1 glycoprotein gp41 loop region are modulated by its intrinsic hydrophobic core. J Biol Chem. 2013;288(40):29143–50.PubMedCentralCrossRefPubMed Qiu J, Ashkenazi A, Liu S, Shai Y. Structural and functional properties of the membranotropic HIV-1 glycoprotein gp41 loop region are modulated by its intrinsic hydrophobic core. J Biol Chem. 2013;288(40):29143–50.PubMedCentralCrossRefPubMed
30.
go back to reference Ashkenazi A, Faingold O, Kaushansky N, Ben-Nun A, Shai Y. A highly conserved sequence associated with the HIV gp41 loop region is an immunomodulator of antigen-specific T cells in mice. Blood. 2013;121(12):2244–52.CrossRefPubMed Ashkenazi A, Faingold O, Kaushansky N, Ben-Nun A, Shai Y. A highly conserved sequence associated with the HIV gp41 loop region is an immunomodulator of antigen-specific T cells in mice. Blood. 2013;121(12):2244–52.CrossRefPubMed
31.
go back to reference Sen J, Yan T, Wang J, Rong L, Tao L, Caffrey M. Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. Biochemistry. 2010;49(24):5057–65.CrossRefPubMed Sen J, Yan T, Wang J, Rong L, Tao L, Caffrey M. Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. Biochemistry. 2010;49(24):5057–65.CrossRefPubMed
32.
go back to reference Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem. 2005;280(12):11259–73.CrossRefPubMed Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem. 2005;280(12):11259–73.CrossRefPubMed
33.
go back to reference Yuan W, Craig S, Si Z, Farzan M, Sodroski J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol. 2004;78(10):5448–57.PubMedCentralCrossRefPubMed Yuan W, Craig S, Si Z, Farzan M, Sodroski J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol. 2004;78(10):5448–57.PubMedCentralCrossRefPubMed
34.
go back to reference Moseri A, Biron Z, Arshava B, Scherf T, Naider F, Anglister J. The C4 region as a target for HIV entry inhibitors – NMR Mapping of the interacting segments of T20 and gp120. FEBS Journal. 2015;282(24):4643–57. Moseri A, Biron Z, Arshava B, Scherf T, Naider F, Anglister J. The C4 region as a target for HIV entry inhibitors – NMR Mapping of the interacting segments of T20 and gp120. FEBS Journal. 2015;282(24):4643–57.
35.
go back to reference Xu Y, Zhang X, Matsuoka M, Hattori T. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett. 2000;487(2):185–8.CrossRefPubMed Xu Y, Zhang X, Matsuoka M, Hattori T. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett. 2000;487(2):185–8.CrossRefPubMed
36.
go back to reference Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med. 1997;186(8):1373–81.PubMedCentralCrossRefPubMed Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med. 1997;186(8):1373–81.PubMedCentralCrossRefPubMed
37.
go back to reference Picard L, Simmons G, Power CA, Meyer A, Weiss RA, Clapham PR. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol. 1997;71(7):5003–11.PubMedCentralPubMed Picard L, Simmons G, Power CA, Meyer A, Weiss RA, Clapham PR. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol. 1997;71(7):5003–11.PubMedCentralPubMed
38.
go back to reference Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R, et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem. 2001;276(2):1391–7.CrossRefPubMed Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R, et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem. 2001;276(2):1391–7.CrossRefPubMed
39.
go back to reference Kliger Y, Shai Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol. 2000;295(2):163–8.CrossRefPubMed Kliger Y, Shai Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol. 2000;295(2):163–8.CrossRefPubMed
40.
go back to reference Roche J, Louis JM, Grishaev A, Ying J, Bax A. Dissociation of the trimeric gp41 ectodomain at the lipid–water interface suggests an active role in HIV-1 Env-mediated membrane fusion. Proc Natl Acad Sci. 2014;111(9):3425–30.PubMedCentralCrossRefPubMed Roche J, Louis JM, Grishaev A, Ying J, Bax A. Dissociation of the trimeric gp41 ectodomain at the lipid–water interface suggests an active role in HIV-1 Env-mediated membrane fusion. Proc Natl Acad Sci. 2014;111(9):3425–30.PubMedCentralCrossRefPubMed
41.
go back to reference Cai L, Gochin M, Liu K. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr Top Med Chem. 2011;11(24):2959–84.PubMedCentralCrossRefPubMed Cai L, Gochin M, Liu K. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr Top Med Chem. 2011;11(24):2959–84.PubMedCentralCrossRefPubMed
42.
go back to reference Kliger Y, Peisajovich SG, Blumenthal R, Shai Y. Membrane-induced conformational change during the activation of HIV-1 gp41. J Mol Biol. 2000;301(4):905–14.CrossRefPubMed Kliger Y, Peisajovich SG, Blumenthal R, Shai Y. Membrane-induced conformational change during the activation of HIV-1 gp41. J Mol Biol. 2000;301(4):905–14.CrossRefPubMed
43.
go back to reference Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997;89(2):263–73.CrossRefPubMed Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997;89(2):263–73.CrossRefPubMed
44.
go back to reference Chesebro B, Wehrly K, Nishio J, Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol. 1996;70(12):9055–9.PubMedCentralPubMed Chesebro B, Wehrly K, Nishio J, Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol. 1996;70(12):9055–9.PubMedCentralPubMed
45.
go back to reference Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 1991;349(6305):167–9.CrossRefPubMed Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 1991;349(6305):167–9.CrossRefPubMed
46.
go back to reference Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Series B Methodol. 1995;57(1):289–300. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Series B Methodol. 1995;57(1):289–300.
47.
go back to reference Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010;6(5):e1000880.PubMedCentralCrossRefPubMed Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010;6(5):e1000880.PubMedCentralCrossRefPubMed
48.
go back to reference Caffrey M, Cai M, Kaufman J, Stahl SJ, Wingfield PT, Covell DG, et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 1998;17(16):4572–84.PubMedCentralCrossRefPubMed Caffrey M, Cai M, Kaufman J, Stahl SJ, Wingfield PT, Covell DG, et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 1998;17(16):4572–84.PubMedCentralCrossRefPubMed
49.
go back to reference 49. Jacobson MP, Pincus DL, Rapp CS, Day TJF, Honig B, Shaw DE, Friesner RA. A hierarchical approach to all-atom protein loop prediction. Proteins: Struct Funct Bioinf. 2004;55(2):351-67. 49. Jacobson MP, Pincus DL, Rapp CS, Day TJF, Honig B, Shaw DE, Friesner RA. A hierarchical approach to all-atom protein loop prediction. Proteins: Struct Funct Bioinf. 2004;55(2):351-67.
Metadata
Title
Statistical correlation of nonconservative substitutions of HIV gp41 variable amino acid residues with the R5X4 HIV-1 phenotype
Authors
Elena Pacheco-Martínez
Evangelina Figueroa-Medina
Carlos Villarreal
Germinal Cocho
José L. Medina-Franco
Oscar Méndez-Lucio
Leonor Huerta
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2016
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-016-0486-6

Other articles of this Issue 1/2016

Virology Journal 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.